The FDA decision on Esperion Therapeutics Inc.’s (ESPR) Supplemental New Drug Applications seeking to add the use of both Nexletol and Nexlizet for cardiovascular risk reduction is expected on March 31, 2024.Nexletol and Nexlizet are oral non-statin products, already approved as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease, who require additional lowering of LDL-C.The company has filed for the broad cardiovascular risk reduction labels in Europe too and a regulatory decision is anticipated in the first half of this year.The proposed expanded use meaningfully increases addressable patient population.ESPR closed Tuesday's (Feb.27, 2024) trading at $2.90, up 10.27%.